2022 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(1ÀÏÂ÷) : 2022-12-02±³À°ÀÏÀÚ : 2022-12-02
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼¿ï È£ÅÚ ±×·£µåȦ
±³À°ÁÖÁ¦ :
2022 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ
´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520
À̸ÞÀÏ :
retina@retina.or.kr ±³À°Á¾·ù : ¾È°ú
Âü¼®¿¹»óÀοø : 350¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 36ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í ȸºñ³³ºÎ ȸ¿ø µî·Ïºñ ¸éÁ¦Àü°ø,ÀüÀÓÀÇ 8¸¸¿øÀü¹®ÀÇ 10¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:10~09:17 Incidence of Retinal Artery Occlusion and Related Mortality: Data from the Entire Korean Population between 2005 and 2018 Ȳ´öÁø(Çѱæ¾È°úº´¿ø)
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:17~09:24 Psoriasis increased risk for neovascular AMD and Retinal vein occlusion in Diabetic Patients : A nationwide population-based study À̹̿¬(°¡Å縯´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:24~09:31 Sphingosine-1-phosphate expression in human epiretinal membranes Àü¼ÒÈñ(Ä«À̾Ȱú)
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:31~09:38 Update on Seoul Artificial Retina Project ¼¿ïÀΰø¸Á¸· ¿¬±¸ÀÇ ÃÖ±Ù »óȲ ¼Á¾¸ð(¼¿ï´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:38~09:45 Does the retina reflect past blood pressure conditions? Á¶¹üÁÖ(ÇѸ²´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 09:45~09:52 Correlated activity in the degenerate retina inhibits focal response to electrical stimulation ±¸¿ë¼÷(ÃæºÏ´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:00~10:09 ERM ¼ö¼ú Áß °©Àڱ⠹߻ýÇÑ eyeball collapse Á¤¾Æ¸§(¿µ³²´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:09~10:18 Sticky silicone oil¿¡ ´ëóÇÏ´Â ¹ý ÃÖÀº¿µ(¿¬¼¼´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:18~10:27 Chandelier-assisted scleral buckling for RRD patient with atopic dermatitis °¿ë±¸(°æºÏ´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:27~10:36 A case of vitrectomy using artificial cornea in a patient with total corneal opacity due to corneal ulcer ±è·¡¿µ(°¡Å縯´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:36~10:45 Schlieren phenomenon in vitreomacular traction: is this subretinal fluid? ¹®¿ë¼®(ÇѸ²´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 10:45~10:54 A case of a frustrating repair of the patient with suprachoroidal hemorrhage ¾çÁö¸í(µ¿±¹´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 11:05~11:30 Molecular Mechanisms of Pathologic Retinal Angiogenesis Leo A. Kim(Harvard Medical School)
±³À°½Ã°£ 12-02 ±×·£µåȦ 11:30~11:43 Bisretinoids: visual cycle adducts and implications for retinal diseases ±èÇýÁø(°è¸í´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 11:43~11:56 Retinal degeneration by intraflagellar transport defects of photoreceptors ÀÌÁØ¿±(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 12-02 ±×·£µåȦ 11:56~12:09 Gene-edited human retinal organoid and mouse models to study inherited retinal diseases ÀÌÁØ¿ø(¿¬¼¼´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 12:15~12:35 Unmet Needs in PCV & Brolucizumab Clinical Evidence in PCV ±è¼ºÅÃ(Á¶¼±´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 12:35~12:55 Optimizing management using Brolucizumab in recalcitrant nAMD ½ÅÁÖ¿µ(¼¿ï´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 13:25~13:49 Using OCT to enhance the outcomes of ERM surgery Stanley Chang(Columbia University)
±³À°½Ã°£ 12-02 ±×·£µåȦ 13:49~14:02 Before deciding to peel the membrane off the macula À̽±Ô(¿¬¼¼´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 14:02~14:15 Special considerations in surgery for ERM: ILM tear ¿©ÁØÇü(Áß¾Ó´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 14:45~14:52 Incidence and Clinical Course of Acute Endophthalmitis after Idiopathic Epiretinal Membrane Surgery with Microincision Vitrectomy ±ÇÇÑÁ¶(ºÎ»ê´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 14:52~14:59 1Â÷ ¼ö¼ú·Î Æó¼âµÇÁö ¾ÊÀº ³Ä¡¼º Ȳ¹Ý¿ø°ø¿¡¼ ÀÚ°¡Ç÷¼ÒÆdzóÃà¾× ÁÖÀÔ¼úÀÇ À¯¿ë¼º ³ªÈ£(°¡Å縯´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 14:59~15:06 Pearls and Pitfalls in ERM surgery with bare RNFL: Practical Tips to Minimize Retinal Damage ¾çÁö¸í(µ¿±¹´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 15:06~15:13 Stress-free ILM flap technique º¯¼®È£(¿¬¼¼´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 15:13~15:20 Topographic Assessment of Intraretinal Cyst Lesions and Its Prognostic Values in Idiopathic Epiretinal Membrane º¯Àͼö(ºÎ»ê´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 15:20~15:27 ¾È±¸ Á¾¾çÀÇ »ý°Ë°ú Áø´Ü ±è¹Î(¿¬¼¼´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 15:35~15:52 À¯¸®Ã¼¸Á¸·ÀÇ °¨¿°¼º Áúȯ¿¡¼ vitreous base shaving - °¡´ÉÇÑ vitreous base±îÁö ±ú²ýÇÏ°Ô Á¦°ÅÇÑ´Ù/- Vitreous base¸¦ ¹«¸®Çؼ Á¦°ÅÇÏÁö ¾Ê´Â´Ù Áö¿µ¼®,Ȳ´öÁø(Àü³²´ë,Çѱæ¾È°úº´¿ø)
±³À°½Ã°£ 12-02 ±×·£µåȦ 15:52~16:09 ¶ó´ÏºñÁÖ¸¿/¾ÖÇø®¹ö¼ÁÆ®¿¡ Ä¡·á ¹ÝÀÀÀÌ Á¦ÇÑÀûÀÎ neovascular AMDÀÇ Ä¡·á - °¡´ÉÇÑ ±âÁ¸ ¾àÁ¦¸¦ ÀÌ¿ëÇÏ¿© Ä¡·á¸¦ Áö¼ÓÇÑ´Ù/ - Àû±ØÀûÀ¸·Î ºê·Ñ·ç½ÃÁÖ¸¿ ±³Ã¼Åõ¿©¸¦ ½ÃÇàÇÑ´Ù À±Ã¢±â,Á¶ÇÑÁÖ(¼¿ï´ë,±è¾È°úº´¿ø)
±³À°½Ã°£ 12-02 ±×·£µåȦ 16:09~16:26 RVO¿¡¼ÀÇ anti-VEGF Ä¡·á - As-needed ÁÖ»ç·Î ÃæºÐÇÏ´Ù/- Proactive Áֻ縦 Àû±ØÀûÀ¸·Î ½ÃÇàÇØ º¼ ¼ö ÀÖ´Ù À̱âȲ,»ç°ø¹Î(¾ÆÁÖ´ë,¿µ³²´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 16:26~16:43 DME ¾ø´Â PDR¿¡¼ PRP ½Ã anti-VEGF ÁÖ»çÀÇ ½Ã±â - PRP Àü¿¡ ¿¹¹æÀûÀ¸·Î ½ÃÇàÇÏ´Â °æ¿ìµµ ¸¹´Ù/- PRP ÈÄ DME°¡ ¹ß»ýÇÏ´Â °æ¿ì¿¡¸¸ ½ÃÇàÇÑ´Ù ±èµ¿À±,±è¿ë±Ô(¼¿ïž¾È°ú,ÇѸ²´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 16:50~16:57 The effect of nondamaging subthreshold laser therapy in patients with chronic central serous chorioretinopathy ³ë¿µÁ¤(°¡Å縯´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 16:57~17:04 DeepPDT-Net: Predicting the Outcome of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Using Two-Stage Multimodal Transfer Learning ÃÖÀº¿µ(¿¬¼¼´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:04~17:11 Clinical applications of metagenomic NGS in fungal endophthalmitis ÀÌÁØ¿±(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:11~17:18 DNA methylome and somatic mutation profiles in the aged retina and choroid ÁÖ±¤½Ä(¼¿ï´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:18~17:25 Differences in the incidence of aflibercept-related sterile endophthalmitis according to types of disposable syringes used ±èÁöÅÃ(Áß¾Ó´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:25~17:32 Molecular characteristics of uveal melanoma in Korean patients À̽±Ô(¿¬¼¼´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:32~17:39 ºñÆÄ¿¼º ³úµ¿¸Æ·ù Ä¡·á·Î ÄÚÀÏ»öÀü¼úÀ» ¹ÞÀº ÈÄ ¹ß»ýÇÏ´Â ¸Á¸·µ¿¸Æ/¼¼µ¿¸Æ Æó¼âÀÇ ºóµµ ¹× Ư¼º ±è¿ëÁØ(¿¬¼¼´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 17:39~17:46 Screening Practices Associated with Late Diagnosis of Hydroxychloroquine Retinopathy: Hospital-based and Population-based studies ¾È¼ºÁØ(ÇѾç´ë)
±³À°½Ã°£ 12-02 ±×·£µåȦ 18:00~18:20 10 years of EYLEA¢ç in Retina Society: unchanged positive long-term benefit-risk profile ±èÀ±Àü(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 12-02 ±×·£µåȦ 18:20~18:40 Optimizing patient care with EYLEA¢ç : flexibility and beyond Á¶ÇÑÁÖ(±è¾È°úº´¿ø)